Screener
BioCryst Pharmaceuticals BCRX ORLADEYO — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| ORLADEYO | $158,202 | $156,837 | $306,549 | $291,080 |
| License and other revenues | 60,048 | 6,516 | 68,114 | 17,807 |
| Total revenues | $218,250 | $163,353 | $374,663 | $308,887 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's ORLADEYO — total revenues?
- BioCryst Pharmaceuticals (BCRX) reported ORLADEYO — total revenues of $158.2M in Q2 2026.
- How has BioCryst Pharmaceuticals's ORLADEYO — total revenues changed year-over-year?
- BioCryst Pharmaceuticals's ORLADEYO — total revenues increased by 0.9% year-over-year, from $156.84M to $158.2M.
- What is the long-term trend for BioCryst Pharmaceuticals's ORLADEYO — total revenues?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's ORLADEYO — total revenues has grown at a 48.9% compound annual growth rate (CAGR), from $122.56M to $601.84M.
- What does ORLADEYO — total revenues mean?
- This metric measures the total gross or net sales generated by the specific product or business segment during a reporting period. It serves as the primary indicator of market adoption and commercial success for the asset.
Ask your AI about BioCryst Pharmaceuticals's orladeyo — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude